Share page on LinkedIn

Partnership insights

Collaborating, innovating, and finding new ways together to improve outcomes

Much more can be achieved when all players in the life sciences and pharmaceutical industries work together, in a truly collaborative way. At ICON, this means working in a way that goes beyond a traditional CRO. It means being a trusted partner.

Sponsor and CRO pharmacovigilance and safety alliances

The evolving relationship between sponsors and CROs

In this Q&A and accompanying podcast, Jeff James provides his perspectives on how CROs have matured to become true partners that offer expansive clinical trial and drug development services, and he spotlights ICON’s approach towards collaboration.

Read the article
Sponsor and CRO pharmacovigilance and safety alliances

Sponsor and CRO pharmacovigilance and safety alliances

This whitepaper outlines the best practices and model options for ensuring success when outsourcing pharmacovigilance and patient safety services.

Read the whitepaper
Harness the power of flow cytometry to drive clinical trials forward

Harness the power of flow cytometry to drive clinical trials forward

The critical role of flow cytometry in clinical trials assessing targeted therapies.

Read the whitepaper
Rare disease registries: practical ways to build trust and collaboration with patient advocacy groups

Rare disease registries: practical ways to build trust and collaboration with patient advocacy groups

With the right planning and understanding, collaboration between drug development companies and patient advocacy groups (PAGs) can be mutually beneficial in a number of key areas.

Watch the webinar
Engaging Physicians to support and increase clinical research activity

Engaging physicians to support and increase clinical research activity

More and more healthcare institutions are looking to increase their research portfolio however engagement of busy physicians is always a challenge.

Watch the webinar

Blogs and media articles